Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147785 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Perla Makhoul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, ENSCM, Université de Montpellier, 34090 Montpellier, France. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Quinoxalines, Caenorhabditis elegans Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency ANR, National Council of Lebanon (CNRS-L), Université de Montpellier doctoral fellowship.
Abstract (Originalsprache)
Imiqualines are analogues of the immunomodulatory drug imiquimod. EAPB02303, the lead of the second-generation imiqualines, is characterized by significant anti-tumor effects with IC50s in the nanomolar range. We used Caenorhabditis elegans transgenic and mutant strains of two key signaling pathways (PI3K-Akt and Ras-MAPK) disrupted in human cancers to investigate the mode of action of EAPB02303. The ability of this imiqualine to inhibit the insulin/IGF1 signaling (IIS) pathway via the PI3K-Akt kinase cascade was explored through assessing the lifespan of wild-type worms. Micromolar doses of EAPB02303 significantly enhanced longevity of N2 strain and led to the nuclear translocation and subsequent activation of transcription factor DAF-16, the only forkhead box transcription factor class O (Fox O) homolog in C. elegans. Moreover, EAPB02303 significantly reduced the multivulva phenotype in let-60/Ras mutant strains MT2124 and MT4698, indicative of its mode of action through the Ras pathway. In summary, we showed that EAPB02303 potently reduced the activity of IIS and Ras-MAPK signaling in C. elegans. Our results revealed the mechanism of action of EAPB02303 against human cancers associated with hyperactivated IIS pathway and oncogenic Ras mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, ENSCM, Université de Montpellier, 34090 Montpellier, France.
- Department of Biology, Faculty of Sciences, GSBT Laboratory, Lebanese University, R. Hariri Campus, Hadath 1533, Lebanon.
- Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Riad El-Solh, P.O. Box 11-0236, Beirut 1107, Lebanon.
ORCID-Profile: Perla Makhoul, Simon Galas, Hiba El Hajj, Myriam Richaud
Förderung
- French National Research Agency ANR
- National Council of Lebanon (CNRS-L)
- Université de Montpellier doctoral fellowship
- Chemistry Research Center at the University of Montpellier
- French National Research Agency (ANR)
Zitieren
APA
Makhoul, P., Galas, S., Paniagua-Gayraud, S., Deleuze-Masquefa, C., Hajj, H. E., Bonnet, P. A., & Richaud, M. (2024). Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147785
Vancouver
Makhoul P, Galas S, Paniagua-Gayraud S, Deleuze-Masquefa C, Hajj HE, Bonnet PA, et al. Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147785
BibTeX
@article{Makhoul2024,
author = {Makhoul, Perla and Galas, Simon and Paniagua-Gayraud, Stéphanie and Deleuze-Masquefa, Carine and Hajj, Hiba El and Bonnet, Pierre-Antoine and Richaud, Myriam},
title = {Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147785}
}
EUVIMED